CapitalSkeptic

@CapitalSkeptic

Individual/Private Investor

Joined January 2026

106 Following

226 Followers

3.4K Posts

Pinned Tweet

CapitalSkeptic

@CapitalSkeptic

about 1 month ago

$HIMS — The Distribution Layer for the Future of Consumer Health The market keeps trading HIMS like it's a compounding pharmacy with a GLP-1 problem. That is not the company. That hasn't been the company for a while. The misread is the trade. Here's what HIMS actually is: the largest consumer-facing health subscription platform in the world, using GLP-1 as a customer acquisition engine while building the infrastructure to become the default healthcare relationship for millions of people across every major health vertical — weight, sexual health, hair, derm, mental health, longevity, and diagnostics. Every new vertical isn't a side bet. It's a cross-sell, a data point, and a retention lever on a subscriber base that compounds. The GLP-1 transition is complete and the bears missed the pivot. HIMS signed a collaboration with Novo Nordisk and shifted to offering FDA-approved GLP-1 medications across its platform — becoming the largest global consumer health platform for access to approved medications. The compounding dependency they were priced to lose is gone. They pivoted from compounding arbitrage to being the distribution layer for branded GLP-1s at scale, with Novo and Lilly as partners, not adversaries. That is a fundamentally different business and a fundamentally different risk profile. Q1 2026 full year guidance was raised to $2.8–$3 billion in revenue — up 19%–28% from 2025 — with adjusted EBITDA guidance of $275–$350 million. On a platform simultaneously absorbing a GLP-1 business model transition, integrating an international acquisition, and investing in three new verticals at once, raising guidance is the signal that the core is stronger than the noise. Now here's the stack the market isn't pricing. Peptides — the next GLP-1 moment. RFK Jr. announced the FDA will convene a Pharmacy Compounding Advisory Committee meeting in July 2026 to review peptides for potential inclusion on the 503A bulk list. HIMS acquired CS Bio — a 30-year-old Menlo Park peptide synthesis house — in February 2025. They own the manufacturing capability. They own the prescriber relationships. They have the CMO already on record calling for physician-led peptide care. When the FDA formalizes the pathway, HIMS is the company that can turn it on fastest. Peptides are the next high-margin, defensible, hard-to-replicate vertical — and they built the factory before anyone else knew the category was opening. International — the TAM doubler nobody's modeling. The Eucalyptus acquisition adds Australia, Japan, and UK exposure at $450M+ ARR, targeting $1B+ international revenue within three years. HIMS launched generic semaglutide in Canada as its first international GLP-1 rollout. The playbook that worked domestically — brand, subscribe, retain, cross-sell — is now being exported to markets with even less direct-to-consumer telehealth competition. International is a free option that's not in anyone's model. The data moat and the GRAIL bet. The GRAIL partnership is one of the most underappreciated pieces of the ecosystem. In February 2026, HIMS launched the Galleri multi-cancer screening test across its platform — combining Trybe Labs at-home blood collection with detection signals for 50+ cancer types, offered at $250 below the $949 list price. This isn't a product add-on. It's the clearest expression of what HIMS is actually building: a single subscriber relationship that spans weight, sexual health, mental health, hormones, and now cancer screening — all feeding the same data layer, all deepening the switching cost. Prescription data, biomarker data, behavioral data, and early cancer detection data on the same person is a clinical intelligence moat that no pharmacy, no hyperscaler, and no government website can replicate. GRAIL needed HIMS for distribution. HIMS needed GRAIL for the longevity stack. The partnership serves both sides — and it plants HIMS squarely in the most valuable real estate in healthcare: the consumer's proactive health relationship, cradle to grave. The ecosystem is building itself. HIMS just added eight new partners expanding its Benefits program across fitness, nutrition, glucose monitoring, women's health, and sleep, while launching Labs AI. Each new partner adds utility to the membership. Each new vertical adds data. Each data point makes the next clinical recommendation smarter. This is a flywheel, and it's turning. The bear case is real: margin compression from the branded GLP-1 transition is a near-term headwind. The Q1 GAAP loss was $92M. Peptides are pre-revenue with regulatory timing risk. The Eucalyptus integration is a multi-year execution story. And HIMS will always carry regulatory headline risk — the FDA can move the goalposts. But here's what the bears are pricing: 2025 HIMS, the compounding arbitrage. Here's what you're buying: 2028 HIMS — the consumer health platform with owned peptide manufacturing, international scale, FDA-approved GLP-1 distribution partnerships, a multi-cancer screening product built on proprietary at-home collection infrastructure, and a data layer that no incumbent, no startup, and no government website can replicate in a decade. The market is giving you the optionality on all of that at a fraction of what the full thesis is worth. I'm long $HIMS. This is a platform story, not a product story. NFA.

CapitalSkeptic

@CapitalSkeptic

Last Seen Users on Sotwe

Trends for you

Most Popular Users